Bio-Techne
TECH · NasdaqBiological Products, (No Diagnostic Substances) · Fiscal year ends Jun 30
Bio-Techne reported revenue of $1.2B in the fiscal year ended Jun 2026, down 0.4% from the year before. Operating income was $252M, an operating margin of 20.7%, and net income was $182M. Operating cash flow of $292M less capital expenditure of $29M left free cash flow of $263M. It held more cash than debt (net cash $65M).
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Cost of revenue | $349M | $367M | $389M | $429M | $416M |
| Gross profit | $756M | $770M | $770M | $790M | $799M |
| Selling, general & admin | $373M | $378M | $466M | $589M | $452M |
| Operating income | $297M | $299M | $207M | $102M | $252M |
| Interest expense | $11M | $11M | $16M | $9M | $10M |
| Pre-tax income | $301M | $339M | $186M | $98M | $241M |
| Income tax | $38M | $53M | $18M | $25M | $59M |
| Net income | $272M | $285M | $168M | $73M | $182M |
| Diluted EPS | 1.66 | 1.76 | 1.05 | 0.46 | 1.16 |
| Diluted shares | 164M | 162M | 161M | 160M | 157M |
Balance sheet
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | $173M | $181M | $152M | $162M | $265M |
| Receivables | $195M | $218M | $241M | $207M | $217M |
| Inventory | $141M | $172M | $180M | $189M | $196M |
| Current assets | $606M | $621M | $617M | $608M | $744M |
| Net PP&E | $223M | $226M | $251M | $246M | $232M |
| Goodwill | $822M | $873M | $973M | $981M | $975M |
| Total assets | $2.3B | $2.6B | $2.7B | $2.6B | $2.6B |
| Payables | $34M | $26M | $38M | $25M | $27M |
| Deferred revenue | $23M | $23M | $28M | $33M | $36M |
| Current liabilities | $176M | $129M | $159M | $176M | $164M |
| Short-term debt | $13M | – | – | – | – |
| Long-term debt | $243M | $350M | $319M | $346M | $200M |
| Shareholders' equity | $1.7B | $2B | $2.1B | $1.9B | $2.1B |
Cash flow
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Operating cash flow | $325M | $254M | $299M | $288M | $292M |
| Capital expenditure | $45M | $38M | $63M | $31M | $29M |
| Free cash flow | $280M | $216M | $236M | $257M | $263M |
| Depreciation & amortisation | $101M | $107M | $112M | $110M | $97M |
| Stock-based compensation | $42M | $39M | $38M | $41M | $41M |
| Acquisitions | – | $101M | $170M | – | – |
| Share buybacks | $161M | $20M | $80M | $276M | $42M |
| Dividends paid | $50M | $50M | $50M | $50M | $50M |
| Dividend per share | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
Key ratios
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 2.8% | 2.0% | 5.2% | −0.4% |
| Operating income growth (YoY) | – | 0.8% | −30.9% | −50.5% | 146.3% |
| EPS growth (YoY) | – | 6.0% | −40.3% | −56.2% | 152.2% |
| Gross margin | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Operating margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Net margin | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| Return on equityBlank when equity is negative | 16.0% | 14.5% | 8.1% | 3.8% | 8.6% |
| ROCEEBIT ÷ (assets − current liabilities) | 14.0% | 11.9% | 8.1% | 4.3% | 10.4% |
| Free cash flow margin | 25.4% | 19.0% | 20.4% | 21.0% | 21.7% |
| Cash conversion (CFO ÷ net income) | 1.20x | 0.89x | 1.78x | 3.92x | 1.61x |
| Receivable days | 64 | 70 | 76 | 62 | 65 |
| Inventory days | 148 | 171 | 168 | 161 | 172 |
| Payable days | 35 | 26 | 36 | 22 | 23 |
| Interest cover | 26.2x | 26.7x | 13.1x | 12.0x | 26.2x |
| Debt ÷ equity | 0.15x | 0.18x | 0.15x | 0.18x | 0.09x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | $83M | $169M | $167M | $184M | −$65M |
| Current ratio | 3.44x | 4.84x | 3.87x | 3.46x | 4.55x |
Recent filings
More in Biological Products, (No Diagnostic Substances)
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.